Dupixent: a breakthrough in the treatment of chronic spontaneous urticaria in Europe

The European Commission has approved Dupixent, co-developed by Sanofi and Regeneron, as a treatment for moderate to severe chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older. It is the first targeted therapy approved in the EU for this condition in over ten years.

Based on phase 3 studies, the approval demonstrates a significant reduction in itching and hives over 24 weeks compared to placebo. Dupixent inhibits IL4 and IL13, key to type 2 inflammation, and is already used to treat seven chronic inflammatory diseases.

Approximately 270,000 people in the EU suffer from chronic obstructive pulmonary disease (COPD), often without an adequate response to standard antihistamines. Dupixent therefore offers a new option to improve the quality of life for these patients.